Follow-up study to evaluate the resistance and durability of the response to treatment with AbbVie direct-acting anitivirals (ADA) in subjects who participated in phase 2 or phase 3 clinical trials for the treatment of chronic hepatitis C virus infection
Abb Vie Farmaceutica, S.L.U.
Pathology and candidate patients
Dr. Moises Diago
Hospital Quirónsalud Valencia.
AbbVie direct action anitivirals (ADA)
July 8, 2013
Hospital Quirónsalud valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: email@example.com